Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

por Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Publicado 2007

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

por Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Publicado 2008

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)

por Bugat, R, Bataillard, A, Lesimple, T, Voigt, J J, Culine, S, Lortholary, A, Merrouche, Y, Ganem, G, Kaminsky, M C, Negrier, S, Perol, M, Laforêt, C, Bedossa, P, Bertrand, G, Coindre, J M, Fizazi, K
Publicado 2003

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

por Heudel, P-E, Fabbro, M, Roemer-Becuwe, C, Kaminsky, M C, Arnaud, A, Joly, F, Roche-Forestier, S, Meunier, J, Foa, C, You, B, Priou, F, Tazi, Y, Floquet, A, Selle, F, Berton-Rigaud, D, Lesoin, A, Kalbacher, E, Lortholary, A, Favier, L, Treilleux, I, Ray-Coquard, I
Publicado 2017